Impoyz is owned by Primus Pharms.
Impoyz contains Clobetasol Propionate.
Impoyz has a total of 4 drug patents out of which 0 drug patents have expired.
Impoyz was authorised for market use on 28 November, 2017.
Impoyz is available in cream;topical dosage forms.
Impoyz can be used as treatment of moderate plaque psoriasis; treatment of plaque psoriasis; psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; twice daily topical treatment of moderate to severe plaque psoriasis., treatment of moderate plaque psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; psoriasis; twice daily topical treatment of moderate to severe plaque psoriasis.; treatment of plaque psoriasis; plaque psoriasis, treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.
The generics of Impoyz are possible to be released after 11 March, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10064875 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(7 years from now) | |
US9956231 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(7 years from now) | |
US10588914 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(7 years from now) | |
US9855334 | PRIMUS PHARMS | Topical compositions comprising a corticosteroid |
Mar, 2035
(12 years from now) |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: Treatment of moderate plaque psoriasis; Treatment of plaque psoriasis; Psoriasis; Treatment of plaque psoriasis in patients 18 years of age or older; Twice daily topical treatment of moderate to severe plaque psoriasis.; Plaque psoriasis; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older
Dosage: CREAM;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic